Gyre Therapeutics 株価情報 (NASDAQ: GYRE)

最新ニュース Gyre Therapeutics (NASDAQ:GYRE) 株価情報

Gyre Therapeutics

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Gyre Therapeutics Inc

TriplePoint Venture Gwth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPVG#NYSE">TPVG</a>) reported quarterly earnings of $0.27 per share which missed the analyst consensus estimate of $0.31 by 12.9 percent. This is a 34.15 percent decrease over earnings of $0.41 per share from the same period last year. The company reported quarterly sales of $22.45 million which missed the analyst consensus estimate of $24.81 million by 9.50 percent. This is a 23.29 percent decrease over sales of $29.27 million the same period last year.

Earnings

Earnings Misses

News

TPVG

TriplePoint Venture Gwth Q1 EPS $0.27 Misses $0.31 Estimate, Sales $22.45M Miss $24.81M Estimate

Century Aluminum (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENX#NASDAQ">CENX</a>) reported quarterly earnings of $0.36 per share which missed the analyst consensus estimate of $0.56 by 35.71 percent. This is a 1300 percent increase over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $633.90 million which beat the analyst consensus estimate of $577.60 million by 9.75 percent. This is a 29.50 percent increase over sales of $489.50 million the same period last year.

Earnings Beats

CENX

Century Aluminum Q1 Adj. EPS $0.36 Misses $0.56 Estimate, Sales $633.90M Beat $577.60M Estimate

Magnite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.07 by 71.43 percent. This is a 140 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $155.77 million which beat the analyst consensus estimate of $144.20 million by 8.02 percent. This is a 4.32 percent increase over sales of $149.32 million the same period last year.

MGNI

Magnite Q1 Adj. EPS $0.12 Beats $0.07 Estimate, Sales $155.77M Beat $144.20M Estimate

WIIM

Zillow Group shares are trading lower after the company reported Q1 financial results and issued Q2 sales guidance with its midpoint below estimates.

Hippo Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIPO#NYSE">HIPO</a>) reported quarterly losses of $(1.91) per share which missed the analyst consensus estimate of $(0.50) by 282 percent. This is a 29.93 percent decrease over losses of $(1.47) per share from the same period last year. The company reported quarterly sales of $110.00 million which missed the analyst consensus estimate of $114.65 million by 4.06 percent. This is a 29.26 percent increase over sales of $85.10 million the same period last year.

HIPO

Hippo Holdings Q1 EPS $(1.91), Sales $110.00M Miss $114.65M Estimate

Guidance

IONQ

IonQ Sees Q2 Sales $16.000M-$18.000M vs $16.93M Est

IonQ Affirms FY2025 Sales Guidance of $75.00M-$95.00M vs $85.42M Est

Silvaco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>) lowers FY2025 Adj EPS guidance from $0.07-$0.19 to $(0.07)-$0.03 vs $0.14 analyst estimate. Lowers FY2025 sales outlook from $66.00 million-$72.00 million to $64.00 million-$70.00 million vs $69.49 million estimate.

SVCO

Silvaco Group Lowers FY2025 Adj EPS Guidance from $0.07-$0.19 to $(0.07)-$0.03 vs $0.14 Est; Lowers FY2025 Sales Guidance from $66.00M-$72.00M to $64.00M-$70.00M vs $69.49M Est

Saratoga Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAR#NYSE">SAR</a>) reported quarterly earnings of $0.56 per share which missed the analyst consensus estimate of $0.70 by 20 percent. This is a 40.43 percent decrease over earnings of $0.94 per share from the same period last year. The company reported quarterly sales of $31.30 million which missed the analyst consensus estimate of $33.22 million by 5.79 percent. This is a 15.95 percent decrease over sales of $37.23 million the same period last year.

Saratoga Investment Q4 Adj. EPS $0.56 Misses $0.70 Estimate, Sales $31.30M Miss $33.22M Estimate

CVNA

Carvana shares are trading lower. The company reported Q1 financial results.

Outset Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) reported quarterly losses of $(3.24) per share which missed the analyst consensus estimate of $(0.94) by 244.68 percent. This is a 62.11 percent increase over losses of $(8.55) per share from the same period last year. The company reported quarterly sales of $29.75 million which beat the analyst consensus estimate of $27.81 million by 6.98 percent. This is a 5.62 percent increase over sales of $28.17 million the same period last year.

Outset Medical Q1 Adj. EPS $(3.24) Misses $(0.94) Estimate, Sales $29.75M Beat $27.81M Estimate

AMC Enter Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.59) by 1.69 percent. This is a 25.64 percent increase over losses of $(0.78) per share from the same period last year. The company reported quarterly sales of $862.50 million which beat the analyst consensus estimate of $837.05 million by 3.04 percent. This is a 9.34 percent decrease over sales of $951.40 million the same period last year.

AMC Enter Hldgs Q1 Adj. EPS $(0.58) Beats $(0.59) Estimate, Sales $862.50M Beat $837.05M Estimate

APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) reported quarterly earnings of $0.44 per share which missed the analyst consensus estimate of $0.83 by 46.99 percent. This is a 43.59 percent decrease over earnings of $0.78 per share from the same period last year. The company reported quarterly sales of $1.38 billion which missed the analyst consensus estimate of $2.20 billion by 37.44 percent. This is a 27.69 percent decrease over sales of $1.90 billion the same period last year.

APA Q1 EPS $0.44 Misses $0.83 Estimate, Sales $1.38B Miss $2.20B Estimate

Armada Hoffler Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHH#NYSE">AHH</a>) affirms FY2025 FFO guidance from $1.00-$1.10 to $1.00-$1.10 vs $1.06 analyst estimate..

Armada Hoffler Properties Affirms FY2025 FFO Guidance of $1.00-$1.10 vs $1.06 Est

Based on our first quarter 2025 results and our outlook for the remainder of the year, we are reaffirming 2025 full year guidance for all financial measures.
<ul>
<li>Total Revenue of $925 million to $935 million</li>
<li>Adjusted EBITDA of $410 million to $420 million</li>
<li>Adjusted EPS of $1.30 to $1.35</li>
<li>Free Cash Flow of $175 million to $185 million</li>
</ul>

VRRM

Verra Mobility Affirms FY2025 Adj EPS Guidance of $1.30-$1.35 vs $1.32 Est; Affirms FY2025 Sales Guidance of $925.00M-$935.00M vs $931.57M Est

ON24 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTF#NYSE">ONTF</a>) Q2 expected to be below $0.02 vs $0.01 Est. sees Q2 sales of $33.800 million-$34.400 million vs $35.17 million analyst estimate.

ONTF

ON24 Q2  expected to be below $0.02 vs $0.01 Est; Sees Q2 Sales $33.800M-$34.400M vs $35.17M Est

AXON

Axon Enterprise shares are trading higher after the company reported better-than-expected Q1 financial results and raised FY25 sales guidance.

Silvaco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>) is looking for Q2 Adj EPS of $(0.10)-$(0.03) vs $0.04 analyst estimate. sees sales of $12.000 million-$16.000 million vs $17.20 million analyst estimate.

Silvaco Group Sees Q2 Adj EPS $(0.10)-$(0.03) vs $0.04 Est; Sees Sales $12.000M-$16.000M vs $17.20M Est

Armada Hoffler Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHH#NYSE">AHH</a>) reported quarterly earnings of $0.25 per share which missed the analyst consensus estimate of $0.26 by 3.85 percent. This is a 24.24 percent decrease over earnings of $0.33 per share from the same period last year. The company reported quarterly sales of $63.80 million which beat the analyst consensus estimate of $63.18 million by 0.98 percent. This is a 3.10 percent increase over sales of $61.88 million the same period last year.

Armada Hoffler Properties Q1 FFO $0.25 Misses $0.26 Estimate, Sales $63.80M Beat $63.18M Estimate

ON24 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTF#NYSE">ONTF</a>) affirms FY2025 Adj EPS guidance from $0.02-$0.05 to $0.02-$0.05 vs $0.03 analyst estimate. Lowers FY2025 sales outlook from $138.60 million-$141.60 million to $133.70 million-$136.70 million vs $139.82 million estimate.

ON24 Affirms FY2025 Adj EPS Guidance of $0.02-$0.05 vs $0.03 Est; Lowers FY2025 Sales Guidance from $138.60M-$141.60M to $133.70M-$136.70M vs $139.82M Est

Press Releases

Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Events

Sidoti Events, LLC's Virtual August Micro-Cap Conference

Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference

Health Care

Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Management

Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology

Comments

Gyre Therapeutics

ニュース

最新ニュース Gyre Therapeutics (NASDAQ:GYRE) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル